Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy.

ABSTRACT: The study of immune evasion has gained a well-deserved eminence in cancer research by successfully developing a new class of therapeutics, immune checkpoint inhibitors, such as pembrolizumab and nivolumab, anti-PD-1 antibodies. By aiming at the immune checkpoint blockade (ICB), these new therapeutics have advanced cancer treatment with notable increases in overall survival and tumor remission. However, recent reports reveal that 40-60% of patients fail to benefit from ICB therapy due to acquired resistance or tumor relapse. This resistance may stem from increased expression of co-inhibitory immune checkpoints or alterations in the tumor microenvironment that promotes immune suppression. Because these mechanisms are poorly elucidated, the transcription factors that regulate immune checkpoin

SUBMITTER: Venkatraman S 

PROVIDER: S-EPMC7761936 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature